GCP
RKDA icon

GSA Capital Partners’s Arcadia Biosciences RKDA Stock Holding History

GSA Capital Partners’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,204
Closed -$324K – 1428
2020
Q4 		$324K Buy
3,204
+678
+27% +$82.8K 0.05% 697
2020
Q3 		$283K Buy
+2,526
New +$341K 0.05% 780

Other funds holding RKDA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MSAM
Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BCM
Bayesian Capital Management Brooklyn, New York $81.9M AUM 26.59% 1-Year Est. Return

GSA Capital Partners's RKDA Position: Q1 2021 in Review

GSA Capital Partners sold out of Arcadia Biosciences (RKDA) in Q1 2021, closing a stake of 3,204 shares — an estimated $324K sold.

GSA Capital Partners first reported a position in RKDA in Q3 2020 and held it in 2 quarters. The position peaked at $324K in Q4 2020. 23 funds tracked by Wall St. Rank hold RKDA as of Q1 2021.

  • GSA Capital Partners reported no remaining Arcadia Biosciences position as of Q1 2021 after selling out during the quarter.
  • GSA Capital Partners sold 3,204 Arcadia Biosciences shares in Q1 2021, an estimated $324K.
  • GSA Capital Partners first reported a position in Arcadia Biosciences in Q3 2020 and held it in 2 quarters.
  • GSA Capital Partners's Arcadia Biosciences position peaked at $324K in Q4 2020.
  • 23 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.